KREJČÍ, Marta, Vlastimil ŠČUDLA, Elen TOTHOVA, Miroslava SCHUTZOVÁ, Vladimír KOZA, Zdeněk ADAM, Andrea KŘIVANOVÁ, Luděk POUR, Tomáš BÜCHLER, Viera SANDECKÁ, Dana KRÁLOVÁ, Lenka ZAHRADOVÁ, Jiří VORLÍČEK, Jiří MAYER and Roman HÁJEK. Long-term outcomes of autologous tranplantation in multiple myeloma: Significant survival benefit of novel drugs in post-transplantation relapse. Clinical Lymphoma & Myeloma. United States: CIG MEDIA GROUP, LP, 2009, vol. 9, No 6, p. 436-442. ISSN 1557-9190. |
Other formats:
BibTeX
LaTeX
RIS
@article{856636, author = {Krejčí, Marta and Ščudla, Vlastimil and Tothova, Elen and Schutzová, Miroslava and Koza, Vladimír and Adam, Zdeněk and Křivanová, Andrea and Pour, Luděk and Büchler, Tomáš and Sandecká, Viera and Králová, Dana and Zahradová, Lenka and Vorlíček, Jiří and Mayer, Jiří and Hájek, Roman}, article_location = {United States}, article_number = {6}, keywords = {bortezomib; complete response; thalidomide}, language = {eng}, issn = {1557-9190}, journal = {Clinical Lymphoma & Myeloma}, title = {Long-term outcomes of autologous tranplantation in multiple myeloma: Significant survival benefit of novel drugs in post-transplantation relapse.}, volume = {9}, year = {2009} }
TY - JOUR ID - 856636 AU - Krejčí, Marta - Ščudla, Vlastimil - Tothova, Elen - Schutzová, Miroslava - Koza, Vladimír - Adam, Zdeněk - Křivanová, Andrea - Pour, Luděk - Büchler, Tomáš - Sandecká, Viera - Králová, Dana - Zahradová, Lenka - Vorlíček, Jiří - Mayer, Jiří - Hájek, Roman PY - 2009 TI - Long-term outcomes of autologous tranplantation in multiple myeloma: Significant survival benefit of novel drugs in post-transplantation relapse. JF - Clinical Lymphoma & Myeloma VL - 9 IS - 6 SP - 436-442 EP - 436-442 PB - CIG MEDIA GROUP, LP SN - 15579190 KW - bortezomib KW - complete response KW - thalidomide N2 - Autologous stem cell transplantation (autoSCT) has an important role in the treatment of patients with symptomatic multiple myeloma (MM). Treatment options for myeloma have expanded in the past decade, and it seems that patients who are treated with novel drugs such as thalidomide and bortezomib for relapse after autoSCT have longer overall survival (OS). ER -
KREJČÍ, Marta, Vlastimil ŠČUDLA, Elen TOTHOVA, Miroslava SCHUTZOVÁ, Vladimír KOZA, Zdeněk ADAM, Andrea KŘIVANOVÁ, Luděk POUR, Tomáš BÜCHLER, Viera SANDECKÁ, Dana KRÁLOVÁ, Lenka ZAHRADOVÁ, Jiří VORLÍČEK, Jiří MAYER and Roman HÁJEK. Long-term outcomes of autologous tranplantation in multiple myeloma: Significant survival benefit of novel drugs in post-transplantation relapse. \textit{Clinical Lymphoma \&{} Myeloma}. United States: CIG MEDIA GROUP, LP, 2009, vol.~9, No~6, p.~436-442. ISSN~1557-9190.
|